From: FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
Treatment
Rates ratio
95 % CI
P value
Control
7.0
1.8 ± 27.0
0.005
Gemcitabine
2.7
1.0 ± 8.7
0.09
Gemcitabine + FRAX
1.0 (ref)